Combined Treatment With Sulpiride and Paroxetine for Accelerated Response in Patients With Major Depressive Disorder

  title={Combined Treatment With Sulpiride and Paroxetine for Accelerated Response in Patients With Major Depressive Disorder},
  author={Hiroyuki Uchida and Hiroyoshi Takeuchi and Takefumi Suzuki and Kensuke Nomura and Koichiro Watanabe and Haruo Kashima},
  journal={Journal of Clinical Psychopharmacology},
Abstract: Although serotonin reuptake inhibitors are recommended as first-line agents for major depressive disorder, delayed onset of action is problematic, and faster effective treatment is needed. Sulpiride, a dopamine-mediated agent, has been reported to show faster antidepressant efficacy, and we examined the efficacy of adjunctive sulpiride in combination with paroxetine (PAX), compared with PAX alone, to clarify whether the combined treatment exerts faster effect. Forty-one major… 

Potential risks of adjunctive use of atypical antipsychotic drugs for the treatment of depression

Aripiprazole Augmentation for Treatment-Resistant Bipolar Depression Sustained Remission After 36 Months

10 additional cases of hypophosphatemia associated with NMS are reported with phosphate levels reported in 3 cases and some potential implications of this finding are reviewed.

Time course of response to paroxetine: Influence of plasma level

Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence.

The Task Force on Antidepressant Medications was established to examine all aspects of therapy with antidepressant drugs and to provide mental health and other professionals with comprehensive and objective information about the different aspects of the use of antidepressants important in clinical practice.

General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry

The spectrum of different antidepressant treatments has broadened over the last few decades and the efficacy and clinical effectiveness of antidepressants is statistically significant, clinically relevant, and proven repeatedly.

Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders

It can be summarized that the spectrum of different antidepressant treatments has broadened during the last decades and a modern individualized antidepressant treatment in most cases is a well-tolerated and efficacious tool to minimize the negative impact of the otherwise devastating and life-threatening outcome of depressive disorders.

Comparison of Physician-Rating and Self-Rating Scales for Patients With Major Depressive Disorder

Examination of discrepancies between physician-rating scales and self-rated scales for symptoms and functioning, before and after treatment, in newly hospitalized patients with major depressive disorder found Physician-rating Scale were more sensitive in detecting symptom or functional changes than self-rating scale.



Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial.

Methylphenidate augmentation of citalopram may be a safe and viable strategy for accelerating antidepressant response in elderly depressed patients and needs to be confirmed in a placebo-controlled trial.

Milnacipran. A review of its use in depression.

Although further published data are required to confirm its efficacy, good tolerability profile and pharmacokinetic profile which suggests a low potential for drug interactions, milnacipran should be considered a promising agent for the treatment of patients with major depressive disorder.

Paroxetine: An Overview of the Efficacy and Safety of a New Selective Serotonin Reuptake Inhibitor in the Treatment of Depression

  • C. Nemeroff
  • Psychology, Medicine
    Journal of clinical psychopharmacology
  • 1993
In clinical studies involving over 6,700 patients worldwide, the efficacy of paroxetine has been shown consistently to be superior to placebo and comparable to tricyclic anti-depression agents in the treatment of depression.

Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression.

A preliminary randomized, placebo-controlled trial to determine the safety and antidepressant efficacy of pramipexole in treatment-resistant bipolar depression found it was a safe and effective antidepressant among patients with bipolar depression.

Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial.

This trial proved that sulpiride is effective and well-tolerated when given in a mean dose of 181 mg per day for mild and moderate depression.

A randomized double blind group comparative study of sulpiride and amitriptyline in affective disorder

Sulpiride showed equivalent antidepressant activity to amitriptyline at 4, 6 and 12 weeks, using the Hamilton Rating Scale (HRS) and the Wakefield Self-Rating Scale for depression (WRS).

Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation.

The present case series suggests that adjunctive stimulants may be a reasonable therapeutic option for treating residual depression and medication-induced sedation in some patients with bipolar disorder.

The safety profile of paroxetine.

Paroxetine has a very favorable side effect profile and should be an important alternative in the medical treatment of depressive illness.